Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?. (September 2016)

• Record Type: Journal Article
• Authors: Cascales-Campos, P.; López-López, V.; Gil, J.; Arévalo-Pérez, J.; Nieto, A.; Barceló, F.; Gil, E.; Parrilla, P.
• Is Part Of: Surgical oncology. Volume 25:Number 3(2016)
• Page Start: 164
• Page End: 170
• Publication Date: 2016-09
• Subjects: HIPEC -- Paclitaxel -- Cisplatin -- Ovarian cancer -- Disease free survival; Cancer -- Surgery -- Periodicals; Neoplasms -- surgery -- Periodicals; Cancer -- Chirurgie -- Périodiques; Electronic journals; 616.994059
• DOI: 10.1016/j.suronc.2016.05.010
• Languages: English
• ISSNs: 0960-7404

Abstract

Abstract: Objetive: To compare the results of the administration of HIPEC with Paclitaxel or Cisplatin after cytoreduction in patients with stage IIIC-IV ovarian cancer, especially focused on disease-free survival. Patients: We retrospectively analyzed a consecutive series of patients operated after being diagnosed with stage III-C/IV serous epithelial ovarian carcinoma. Patients included in the study were treated between January 2008 and March 2015. After cytoreduction, Paclitaxel (doses of 60 mg/m 2 O or Cisplatin (doses of 75 mg/m 2 ) were used. Results: A total of 111 patients were included. Median age was 61 years. In 60 of them (54%) Paclitaxel was used during HIPEC treatment and 51 patients (46%) were treated with Cisplatin. PCI was similar between groups (PCI = 11 in both cases). Median follow up was 34 months (12–96 months). The median disease free survival in Paclitaxel Group was 27 months and 33 months in Cisplatin Group (p = 0.551). In patients treated with Paclitaxel disease free survival rates at 1, 2, and 3 years were 79%, 60% and 46%. In patients treated with Cisplatin disease free survival at 1, 2, and 3 years were 64%, 50% and 40% respectively. After a multivariate analysis, incomplete cytoreduction (HR: 6.54, 95% CI 2.98–10.17, p < 0.01) and PCI >11 (HR: 2.15, 95% CI 1.42–6.68, p < 0.05) were identified as independent factors associated with a reduced disease-free survival. Cystotatic used was not relevant regarding disease free survival analysis. Conclusion: HIPEC with paclitaxel or cisplatin after cytoreduction in patients with ovarian cancer IIIC-IV has not shown different results in disease-free survival outcomes. Highlights: There is a benefit of HIPEC treatment compared with cytoreduction alone. Incomplete cytoreduction and high PCI reduced disease-free survival. Type of cystotatic is not relevant regarding disease free survival analysis.